

PATIENT REFERRAL CRITERIA¹

Patients with more than one of the following risk factors and who are New York Heart Association (NYHA) Class III or IV should be considered for referral for mechanical circulatory support (MCS) and/or cardiac transplantation evaluation.

Functional Assessment

- Inability to walk one block without shortness of breath
- Intolerant or refractory to ACE inhibitors, angiotensin receptor blockers, or beta-blockers
- One heart-failure-related hospital admission in the past 6 months²
- CRT nonresponder
- High diuretic dose (eg, 120 mg/d furosemide)

Lab Assessment


- Serum sodium < 136 mmol/L
- BUN > 40 mg/dL or serum creatinine > 1.8 mg/dL
- Hematocrit < 35%



HeartMate II[®]
Left Ventricular Assist System

HeartMate II® provides dramatic and sustained improvements in quality of life for advanced stage heart failure patients.³⁻⁶

81%
Improved
to NYHA
Class I or II



Documented MCS Benefits

- Restoration of hemodynamics
- Reduced mortality
- Improvement in cardiac output
- Improvement in quality of life
- Improvement in end organ (renal/hepatic) function



THORATEC
CORPORATION

for Life

References

1. Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action. *Congest Heart Fail.* 2008;14(6):316-321. **2.** Teuteberg JJ, Lewis EF, Nohria A, et al. Characteristics of patients who die with heart failure and low ejection fraction in the new millennium. *J Card Fail.* 2006;12(1):47-53. **3.** Slaughter MS, Rogers JG, Milano CA, et al; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med.* 2009;361(23):2241-2251. **4.** Pagani FD, Miller LW, Russell SD, et al; HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. *J Am Coll Cardiol.* 2009;54(4):312-321. **5.** Miller LW, Pagani FD, Russell SD, et al; HeartMate II Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med.* 2007;357(9):885-896. **6.** Park SJ, Milano CA, Tatroles AJ, et al; for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. *Circ Heart Fail.* 2012;5(2):241-248.

Thoratec Corporation, 6035 Stoneridge Drive, Pleasanton, CA 94588
1-925-847-8600 1-800-528-2577 www.thoratec.com

Thoratec, the Thoratec logo, and HeartMate II are registered trademarks of Thoratec Corporation. ©2012 Thoratec Corporation. All rights reserved. J074-0712